Harmony Biosciences Holdings, Inc. (HRMY)

NASDAQ

$38.92

-$1.59 (3.92%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$38.75$40.87

Open $40.55

52 Week Range

$25.52$40.93

Previous Close $40.51

Market Cap2.24B

Volume1.06M

Avg Volume918.79K

P/E (TTM)12.26

EPS (TTM)$3.18

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Harmony Biosciences Holdings, Inc.

DEC162025

Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG

Source: GlobeNewsWire•6h ago

BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (Nasdaq: HRMY), a pharmaceutical company dedicated to developi...

DEC82025

Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome

Source: Business Wire•8 days ago

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the presentation of initial open-label extension (OLE) data from the company's ongoing Phase 3 ARGUS trial investigating EPX-100 (clemizole hyd...

DEC22025

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

Source: Business Wire•14 days ago

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will highlight new open-label extension data from the company's investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase...

NOV242025

Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

Source: Business Wire•22 days ago

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced positive results from its pivotal bioequivalence (BE) study evaluating pitolisant gastro-resistant (GR) formulation. With positive findings from...

NOV192025

Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence

Source: Business Wire•27 days ago

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced dosing of the first participant in a Phase 1 clinical trial of BP1.15205, an investigational, potentially best-in-class, orexin 2 receptor (OX2R...

NOV182025

Harmony Biosciences to Participate in Upcoming Investor Conferences

Source: Business Wire•28 days ago

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Citi's 2025 Global Healthcare Conference Locati...

NOV42025

Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

Source: Business Wire•42 days ago

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings of $239.5M for Q3 2025, representing 29% year-over-year revenue growth for WAKIX®. These results were driven by the highest ever increa...

OCT232025

Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

Source: Business Wire•54 days ago

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following: WAKIX® (pitolisant) franchise delivered net revenue of approximately $239M in Q3 ...

SEP242025

Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

Source: Business Wire•83 days ago

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). The RECONNECT Study...